TY - JOUR
T1 - Considerations for the clinical application of chimeric antigen receptor T cells
T2 - Observations from a recombinant DNA advisory committee symposium held June 15, 2010
AU - Ertl, Hildegund C.J.
AU - Zaia, John
AU - Rosenberg, Steven A.
AU - June, Carl H.
AU - Dotti, Gianpietro
AU - Kahn, Jeffrey
AU - Cooper, Laurence J.N.
AU - Corrigan-Curay, Jacqueline
AU - Strome, Scott E.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - T cells that are genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials. Unfortunately, 2 recent deaths in cancer patients treated with CAR T cells have created some uncertainty on how to best mitigate patient risk, while continuing to advance this very promising therapeutic avenue. In order to address these concerns, the Recombinant DNA Advisory Committee (RAC) held a symposium, the objectives of which were to first review the reported treatment-associated toxicities and, second, to discuss methods for improving safety and efficacy. This report highlights the issues raised as part of this discussion, with a specific focus on protocols infusing CAR T cells. Because this was not a consensus conference, the opinions described should not be construed to represent those of any individual RAC member, the RAC as a body, conference participants, the National Institutes of Health, or the U.S. Food and Drug Administration.
AB - T cells that are genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials. Unfortunately, 2 recent deaths in cancer patients treated with CAR T cells have created some uncertainty on how to best mitigate patient risk, while continuing to advance this very promising therapeutic avenue. In order to address these concerns, the Recombinant DNA Advisory Committee (RAC) held a symposium, the objectives of which were to first review the reported treatment-associated toxicities and, second, to discuss methods for improving safety and efficacy. This report highlights the issues raised as part of this discussion, with a specific focus on protocols infusing CAR T cells. Because this was not a consensus conference, the opinions described should not be construed to represent those of any individual RAC member, the RAC as a body, conference participants, the National Institutes of Health, or the U.S. Food and Drug Administration.
UR - http://www.scopus.com/inward/record.url?scp=79955512733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955512733&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-10-4035
DO - 10.1158/0008-5472.CAN-10-4035
M3 - Article
C2 - 21531763
AN - SCOPUS:79955512733
SN - 0008-5472
VL - 71
SP - 3175
EP - 3181
JO - Cancer Research
JF - Cancer Research
IS - 9
ER -